Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 29, 2024Dermatology and TherapyOpen Access

Comparison of Drug-Free Remission after the End of Phase III Trials of Three Different Anti-IL-23 Inhibitors in Psoriasis

View Full Paper
Ask AI
Bookmark
Share

Authors

CHChang‐Yu HsiehFHFrancis Li‐Tien HsuTTTsen‐Fang Tsai

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Hsieh et al. (2024) studied this question.

synapsesocial.com/papers/68e5ea33b6db64358757ecc5https://doi.org/10.1007/s13555-024-01229-6
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impact of Biologic Treatment Duration on Drug-Free Remission in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study2026
  2. 2Evaluation of Discontinuation and Re‐Initiation of Biologic Therapies in Psoriasis: Real‐World Data2026 · 2 citations
  3. 3Treatment Discontinuation in Patients with Psoriasis Treated with Biologics: A Retrospective Analysis of German Health Claims Data2024 · 4 citations
  4. 4The Evaluation of the Clinical Effectiveness and Safety of Biologic Therapies in Psoriasis–Real-World Evidence up to 64 Weeks of Therapy2026
  5. 5Drug survival of biologic treatments for psoriasis and psoriatic arthritis in Denmark, 2018–23: a nationwide register–based cohort study2026